Joanne NGEOW   
    Main Page                  
a filler
  Joanne NGEOW  

a a a
  Joanne NGEOW

Brief Biosketch

Associate Professor Joanne Ngeow, is a Senior Consultant in Division of Medical Oncology at the National Cancer Centre Singapore (NCCS). Assoc Prof Ngeow currently heads the NCCS Cancer Genetics Service with an academic interest in hereditary cancer syndromes and translational clinical cancer genomics. Her current clinical focus and research revolves around understanding cancer predisposition by studying cancers clustering in families, young adults and in families with multiple / rare cancer presentations.
After completing her undergraduate medical studies at the University of Melbourne, Australia, in 2001, she completed her Internal Medicine training at the Singapore General Hospital and trained in Medical Oncology at NCCS. She was awarded consecutive fellowships by the SingHealth Research Foundation, National Medical Research Council and the Ambrose Monell Foundation to complete formal clinical and bench training as the Ambrose Monell Cancer Genomic Medicine Fellow at the Genomic Medicine Institute, Cleveland Clinic, Ohio. In 2015, she completed her Masters of Public Health at the Bloomberg School of Public Health, Johns Hopkins University, with a focus in cancer epidemiology and health economics making her one of a handful of individuals globally with skills spanning translational science, clinical genetics and health services research.

In 2014, Assoc Prof Ngeow returned to Singapore to lead the clinical cancer genetics service and research programme at NCCS into inherited cancer syndromes. Assoc Prof Ngeow was appointed as Associate Professor (Genomic Medicine) of Lee Kong Chian School of Medicine, Nanyang Technological University in 2017. She has published over 80 peer reviewed papers in such journals as the Journal of Clinical Oncology, Annals of Oncology, Human Molecular Genetics, Journal of Clinical Endocrinology and Metabolism, Gastroenterology. She is an Associate Editor for Endocrine-Related Cancers.

Project Description


It is estimated that approximately 5-10% of all cancer is hereditary in nature. There are several known hereditary cancer predisposition syndromes, including hereditary breast-ovarian cancer, hereditary non-polyposis colorectal cancer, and familial adenomatous polyposis.  Many of the genes responsible for these syndromes have been identified within the last fifteen years. Similarly, there is a great interest in evaluating genetic predisposition to therapeutic responses and outcomes. The project titled “Hereditary cancer predisposition” is interested in:
1) Identifying and characterizing molecular defects associated with heritable cancers and the corresponding therapeutic responses.
2) Characterizing signaling pathways and mechanisms of action of these cancers and therapeutics.
This work may have broad implications for examining the pathogenesis of common cancers as well as the genetics of therapeutic outcomes, and has the potential to reveal novel targets and novel compartments germane for diagnosis, prognosis, therapy and prevention.